As part of its fourth quarter and full-year earnings release on Thursday, Shire provided information about the early sales of its dry eye disease drug Xiidra (lifitegrast), which was launched in August following FDA approval in July. Revenue from Xiidra totalled $54 million for the year and captured 19 percent of the US market for the indication in the 4 months after its launch.
"In just 5 or so months following the launch, we’ve been able to achieve over 270,000 prescriptions and now command roughly 20 percent of the total market, and 50 percent of new-to-brand market share," Flemming Ornskov, MD, Chief Executive Officer, said during the earnings call. "We continue to see robust growth in prescriptions and an increased number of prescribing physicians, increasing refill rates, and an increasing number of prescriptions per physician."
Xiidra 5% is a twice-daily prescription eye drop indicated for the treatment of the signs and symptoms of dry eye disease. It received FDA approval on July 11, 2016.
Overall, Shire's fourth-quarter revenue more than doubled year-over-year to $3.8 billion, boosted by the purchase of Baxalta. Net income in the 3-month period jumped 63 percent to $457 million. For 2016, sales jumped 78 percent to $11.4 billion, benefiting from the acquisition of Dyax, while net income slipped 75 percent to $327 million.